First, we evaluated if TFEB and the ABC transporters of interest (the drug resistance inducer ABCC1 and the immuno-sensitizer protein ABCA1) were correlated and had a clinical relevance in NSCLC patients. Here, ABCA1 is linked to non-small cell lung carcinoma.